# A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

> **NCT01831973** · PHASE2 · COMPLETED · sponsor: **Taiwan Liposome Company** · enrollment: 18 (actual)

## Conditions studied

- Advanced/Metastasis Renal Cell Carcinoma

## Interventions

- **DRUG:** Lipotecan

## Key facts

- **NCT ID:** NCT01831973
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-30
- **Primary completion:** 2015-03-19
- **Final completion:** 2017-02-21
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01831973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01831973, "A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01831973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*